CN102295695B - 重组人促卵泡激素及其制备 - Google Patents
重组人促卵泡激素及其制备 Download PDFInfo
- Publication number
- CN102295695B CN102295695B CN 201110269900 CN201110269900A CN102295695B CN 102295695 B CN102295695 B CN 102295695B CN 201110269900 CN201110269900 CN 201110269900 CN 201110269900 A CN201110269900 A CN 201110269900A CN 102295695 B CN102295695 B CN 102295695B
- Authority
- CN
- China
- Prior art keywords
- fsh
- preparation
- puregon
- carrier
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 title abstract description 3
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 title abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 74
- 230000000694 effects Effects 0.000 claims abstract description 15
- 102000002287 alpha Subunit Glycoprotein Hormones Human genes 0.000 claims description 41
- 108010000732 alpha Subunit Glycoprotein Hormones Proteins 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 33
- 108010081485 beta Subunit Follicle Stimulating Hormone Proteins 0.000 claims description 30
- 102000035824 beta Subunit Follicle Stimulating Hormone Human genes 0.000 claims description 30
- 238000005571 anion exchange chromatography Methods 0.000 claims description 24
- 108010081934 follitropin beta Proteins 0.000 claims description 21
- 102000002067 Protein Subunits Human genes 0.000 claims description 17
- 108010001267 Protein Subunits Proteins 0.000 claims description 17
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 15
- 238000004587 chromatography analysis Methods 0.000 claims description 15
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 238000002270 exclusion chromatography Methods 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 10
- 108091008146 restriction endonucleases Proteins 0.000 claims description 10
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 claims description 8
- 229920002684 Sepharose Polymers 0.000 claims description 8
- 108010006578 follitropin alfa Proteins 0.000 claims description 8
- 229940057854 gonal f Drugs 0.000 claims description 8
- 230000006303 immediate early viral mRNA transcription Effects 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 238000001890 transfection Methods 0.000 claims description 8
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 7
- 239000012228 culture supernatant Substances 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 6
- 239000012506 Sephacryl® Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 4
- 239000013622 capto Q Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 239000003636 conditioned culture medium Substances 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 18
- 239000013598 vector Substances 0.000 abstract description 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 32
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 32
- 229940028334 follicle stimulating hormone Drugs 0.000 description 32
- 239000000047 product Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 230000029087 digestion Effects 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000012679 serum free medium Substances 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 239000003292 glue Substances 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- -1 wherein Proteins 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010072454 CTGCAG-specific type II deoxyribonucleases Proteins 0.000 description 1
- 238000013449 Capto Q chromatography Methods 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Images
Abstract
Description
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110269900 CN102295695B (zh) | 2011-09-14 | 2011-09-14 | 重组人促卵泡激素及其制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110269900 CN102295695B (zh) | 2011-09-14 | 2011-09-14 | 重组人促卵泡激素及其制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102295695A CN102295695A (zh) | 2011-12-28 |
CN102295695B true CN102295695B (zh) | 2013-07-31 |
Family
ID=45356392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110269900 Active CN102295695B (zh) | 2011-09-14 | 2011-09-14 | 重组人促卵泡激素及其制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102295695B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102786589A (zh) * | 2012-07-30 | 2012-11-21 | 南昌市万华生化药业有限公司 | 重组人促卵泡成熟素rFSH及其基因工程菌株 |
CN105906704A (zh) * | 2016-05-04 | 2016-08-31 | 长春圣金诺生物制药有限公司 | 一种重组人促卵泡激素的纯化方法 |
CN107460206B (zh) * | 2017-09-11 | 2020-05-01 | 深圳市深研生物科技有限公司 | 人fsh的重组表达载体、重组细胞株及重组人fsh的制备方法 |
CN109957580A (zh) * | 2019-05-07 | 2019-07-02 | 西北农林科技大学 | 一种表达人促卵泡生长激素(fsh)的方法 |
CN110305903B (zh) * | 2019-07-31 | 2021-10-01 | 江苏璟泽生物医药有限公司 | 重组人促卵泡激素及其制备方法 |
WO2022141441A1 (zh) * | 2020-12-31 | 2022-07-07 | 南通大学 | 一种促卵泡激素及其体外自组装方法 |
CN112679601A (zh) * | 2021-01-20 | 2021-04-20 | 长春生物制品研究所有限责任公司 | 一种高比活性重组人促卵泡激素的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101250531B (zh) * | 2006-11-27 | 2013-04-24 | 株式会社Lg生命科学 | 一核苷酸序列、包含该序列的表达载体、该载体转化的动物细胞及利用该细胞生产人fsh的方法 |
CN101851287B (zh) * | 2009-04-02 | 2013-06-12 | 上海天伟生物制药有限公司 | 一种高比活绝经期促性腺素及其制备方法和用途 |
-
2011
- 2011-09-14 CN CN 201110269900 patent/CN102295695B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102295695A (zh) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102295695B (zh) | 重组人促卵泡激素及其制备 | |
JP3017962B2 (ja) | ヘマトクリット値を上昇させるための医薬組成物の製造方法 | |
CN106220724B (zh) | 人成纤维细胞生长因子21重组蛋白及其制备方法和应用 | |
CN109851674B (zh) | 一种用于治疗儿童矮小症的重组人血清白蛋白/生长激素融合蛋白的制备纯化方法 | |
CN102816244A (zh) | 一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法 | |
CN110845603A (zh) | 人胶原蛋白17型多肽、其生产方法和用途 | |
CN113265007B (zh) | 一种治疗代谢疾病的融合蛋白及其制备方法和应用 | |
CN113121705B (zh) | 用于制备短肽混合物的融合蛋白、目的多肽、短肽混合物的制备方法及应用 | |
CN101875700B (zh) | 一种增加促胰岛素分泌肽融合蛋白生物活性的方法 | |
CN101240033B (zh) | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 | |
WO2007107882A2 (en) | Method for purifying granulocyte-colony stimulating factor | |
CN101134105B (zh) | 用于治疗和/或预防脑梗塞的含有重组人胰激肽原酶的药物组合物 | |
CN110256575A (zh) | 一种长效重组人生长激素融合蛋白及其工程细胞 | |
CN112851791B (zh) | 一种新型抗代谢紊乱的fgf类似物及其应用 | |
CN101525387A (zh) | 重组长效胰高血糖素样肽类似物及其制备方法 | |
CN1962695B (zh) | 类胰高血素肽-1融合蛋白及其制备和用途 | |
CN101134953B (zh) | 重组人胰激肽原酶 | |
CN104558198A (zh) | GLP-1类似物和amylin类似物的融合蛋白制备及其用途 | |
CN101875699B (zh) | 人表皮生长因子和金属硫蛋白的融合蛋白及其制备方法和应用 | |
CN101451151A (zh) | 一种利用肿瘤细胞生产生物活性产物的方法 | |
CN105884901A (zh) | 具持续控制血糖含量功能的重组人血清白蛋白/胰高糖素类肽融合蛋白 | |
CN101967468A (zh) | 一种重组人胰激肽原酶 | |
CN100535005C (zh) | 长链人胰岛素样生长因子(lr3igf-1)及其制备和应用方法 | |
CN111424035A (zh) | 基于家蚕丝腺表达具有生物学活性的人结缔组织生长因子的方法及其产品和应用 | |
JP2018508465A (ja) | 長時間作用性ctp修飾成長ホルモンポリペプチドを生成する方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: 130012 No. 72 Tianhe street, hi tech Development Zone, Jilin, Changchun Applicant after: Jinsai Drug Co., Ltd., Changchun Address before: 130012 No. 72 Tianhe street, hi tech Development Zone, Jilin, Changchun Applicant before: Changchun Genscience Pharmaceuticals Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHANGCHUN GENSCI PHARMACEUTICAL CO., LTD. TO: JINSAI MEDICINE CO., LTD., CHANGCHUN |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: Changchun Genscience Pharmaceuticals Co., Ltd. Address before: 130012 No. 72 Tianhe street, hi tech Development Zone, Jilin, Changchun Patentee before: Jinsai Drug Co., Ltd., Changchun |
|
CP03 | Change of name, title or address | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: Jinsai Drug Co., Ltd., Changchun Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: Changchun Genscience Pharmaceuticals Co., Ltd. |